SkinnyRx: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://skinnyrx.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.

1. 1

   “The compounded semaglutide and tirzepatide products displayed on your website identify “SkinnyRx” on the pictured label, suggesting SkinnyRx is the compounder of those drugs when in fact it is not.”

2. 2

   ““from the same family as GLP-1 treatments like Mounjaro® and Zepbound®” “Get access to the same active ingredient as name-brand GLP-1 medications” “It contains the same active ingredient as FDA-approved medications””

3. 3

   “Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”

1. 1

   Letter issued

   February 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

skinnyrx.com is a JavaScript application that serves an empty shell to a plain fetch, so we checked its published sitemap and application bundle instead. Both were live in August 2026 and list an active catalogue — injectable and tablet semaglutide and tirzepatide, plus branded options — indicating an operating storefront rather than a closed one.

Take the third claim on its own: a compounded semaglutide product does contain the same active ingredient as an FDA-approved medication. As a sentence about chemistry it survives inspection, which is exactly why it is the one worth thinking about. FDA's objection was not that the sentence is untrue but that the impression it leaves — that approval has touched this product — is not. That is a higher bar than most price pages are written to clear, and it means you cannot screen a seller by looking for obviously overblown language. The hedges here are the careful ones: same family, access to the same ingredient, contains the same ingredient as approved medications. A page can be technically accurate line by line and still leave you believing something about the product's regulatory status that is not so.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence SkinnyRx failed to respond.